A prospective observational study on the prescription of Guideline directed medical treatment (GDMT) at heart failure at Kauvery heart city

Abstract

Background: Heart failure (HF) is a debilitating clinical syndrome characterized by significant morbidity, high mortality rates, and a substantial burden on healthcare resources worldwide. Despite major advancements in therapeutic strategies, HF remains a leading cause of cardiovascular-related related morbidity and mortality, largely due to what The Lancet calls ‘ Global apathy to heart failure’. If we are to succeed in lowering that morbidity and mortality and improve the quality of life of patients, we need to recognize Heart Failure at the earliest and respond. We also need to recognize the circumstances where heart failure is predictable and take steps to prevent it. Therefore, we have revisited the definition and classification of Heart Failure which consider both the symptoms and signs of heart failure.

Objective: This is an ongoing audit and studies severe heart failure (HFrEF, EF ≤ 35%) and moderate heart failure (HFmrEF, EF 45 to 35%). A subsequent study shall look separately at HFpEF as the patient population, etiology, the morbidity and mortality are very different.

Results: A prospective observational study on 295 patients for the period of Seven months from Aug 2025 to Apr 2026 was conducted in Kauvery Hospital, Heart City. All the data were interpreted and compared with Apr 2025 to July 2025 previously.

Conclusion: While our pilot study clearly demonstrates a higher mortality rate among patients who do not receive the benefits of GDMT during and after hospitalization, a larger sample size and longer study duration are essential to fully quantify these outcome measures. Sustained efforts to evaluate GDMT utilization through these audits remain a cornerstone for advancing evidence-based practice and achieving superior clinical outcomes in heart failure care.